Connecting healthcare stakeholders to bring clarity to molecular diagnostic testing
Advanced diagnostics are evolving rapidly and the dramatic growth the industry has seen is expected to continue. In fact, the global market is expected to grow at a compound annual rate of 11% through 2019, generating an estimated $8.7 billion in revenue by 20191. This industry growth is fueled by the excitement of personalized medicine and the many new laboratory developed tests brought to the market regularly. While the industry growth brings innovation and opportunities, the lack of transparency of molecular diagnostic (MDx) tests can create inefficiencies and confusion across the healthcare system.
Studiomaca brings the clarity needed to the molecular diagnostic test industry by uniquely identifying and cataloging MDx tests using Studiomaca Z-Code™ Identifiers – unique 5-character alpha-numeric codes assigned within the Studiomaca Diagnostics Exchange. The Studiomaca Diagnostics Exchange (DEX) is a molecular diagnostic (MDx) test catalog and policy management solution connecting payers and laboratories to drive appropriate MDx coverage and payments.
The Studiomaca Diagnostics Exchange (DEX) enables:
- Unique identification of molecular diagnostic (MDx) tests
- Transparent policy determinations
- Access to InterQual® Clinical Evidence Summaries
- Simplified claims processing for all stakeholders
1. “: Transparency Market Research”; April 15, 2014.